Hostname: page-component-848d4c4894-hfldf Total loading time: 0 Render date: 2024-05-28T06:41:59.142Z Has data issue: false hasContentIssue false

Acetyl L-Carnitine Slows Decline in Younger Patients With Alzheimer's Disease: A Reanalysis of a Double-Blind, Placebo-Controlled Study Using the Trilinear Approach

Published online by Cambridge University Press:  10 January 2005

John O. Brooks
Affiliation:
Stanford University School of Medicine, Stanford, California, USA
Jerome A. Yesavage
Affiliation:
Stanford University School of Medicine, Stanford, California, USA Veterans Affairs Health Care System, Palo Alto, California, USA
Angelico Carta
Affiliation:
Sigma Tau Pharmaceuticals, Gaithersburg, Maryland, USA.
Daniele Bravi
Affiliation:
Sigma Tau Pharmaceuticals, Gaithersburg, Maryland, USA.

Abstract

Objectives: To assess the longitudinal effects of acetyl-L-carnitine (ALC) on patients diagnosed with Alzheimer's disease. Design: Longitudinal, double-blind, parallel-group, placebocontrolled. Setting: Twenty-four outpatient sites across the United States. Participants: A total of 334 subjects diagnosed with probable Alzheimer's disease by NINCDS-ADRDA criteria. These data were originally reported by Thal and colleagues (1996). Measurements: Cognitive subscale of the Alzheimer Disease Assessment Scale (ADAS) given every 3 months for 1 year. Results: The average rate of change was estimated using the trilinear approach, which allows for periods of both change and stability. Both the ALC group and the placebo group exhibited the same mean rate of change on the ADAS (0.68 points/month). However, a multiple regression analysis revealed a statistically significant Age × Drug interaction characterized by younger subjects benefiting more from ALC treatment than older subjects. Further analyses suggested that the optimal, though not statistically significant, cutpoint for ALC benefit was 61 years of age. Conclusions: ALC slows the progression of Alzheimer's disease in younger subjects, and the use of the trilinear approach to estimate the average rate of change may prove valuable in pharmacological trials.

Type
Studies on Dementia
Copyright
© 1998 International Psychogeriatric Association

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)